ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
Find more results for IMGN
6.25
-0.18 (-2.80%)
Real-time:   3:16PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.15 - 6.59
52 week 5.34 - 17.80
Open 6.50
Vol / Avg. 723,257.00/2.18M
Mkt cap 557.03M
P/E     -
Div/yield     -
EPS -0.96
Shares 85.94M
Beta 2.06
Inst. own 90%
Feb 12, 2015
ImmunoGen Inc at Leerink Global Healthcare Conference - 8:30AM EST - Add to calendar
Jan 30, 2015
Q2 2015 ImmunoGen Inc Earnings Call - 8:00AM EST - Add to calendar
Jan 30, 2015
Q2 2015 ImmunoGen Inc Earnings Release - 6:30AM EST - Add to calendar
Jan 13, 2015
ImmunoGen Inc at JPMorgan Healthcare Conference - Q&A Session - Webcast
Jan 13, 2015
ImmunoGen Inc at JPMorgan Healthcare Conference
Nov 11, 2014
Immunogen Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -168.76% -119.15%
Operating margin -165.95% -119.43%
EBITD margin - -111.75%
Return on average assets -57.95% -37.67%
Return on average equity -132.73% -72.25%
Employees 307 -
CDP Score - -

Address

830 WINTER ST
WALTHAM, MA 02451
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoGen, Inc. is a biotechnology company. The Company develops targeted anticancer therapeutics. The Company has three wholly-owned product candidates in clinical testing, with seven additional compounds in the clinic through its partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. The Company�s clinical-stage product candidates, include IMGN289, IMGN853 and IMGN529. IMGN289 compound is a treatment for many cases of head and neck cancers. IMGN853 compound is a potential treatment for epithelial ovarian cancer, endometrial cancer and other cancers. IMGN529 compound is used for the treatment of NHL (non-Hodgkin lymphoma). The Company�s IMGN529 ADC is a new treatment for cancers that express CD37, such as NHL and chronic lymphocytic leukemia.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Daniel M. Junius President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Ellie Harrison Chief Human Resource Officer, Vice President
Age: 59
Bio & Compensation  - Reuters
Richard J Gregory Ph.D. Executive Vice President - Research, Chief Scientific Officer
Bio & Compensation  - Reuters
John M. Lambert Ph.D. Executive Vice President - Distinguished Research Fellow
Age: 63
Bio & Compensation  - Reuters
Sandra E. Poole Senior Vice President - Technical Operations.
Age: 51
Bio & Compensation  - Reuters
Craig Barrows Vice President, General Counsel, Secretary
Age: 59
Bio & Compensation  - Reuters
James J. O'Leary M.D. Vice President, Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Peter J. Williams Vice President - Business Development
Age: 60
Bio & Compensation  - Reuters
Mark Goldberg Independent Director
Age: 60
Bio & Compensation  - Reuters